Skip to main content

Indivior Pharmaceuticals, Inc.

INDV
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001625297

In the last 90 days, Indivior Pharmaceuticals, Inc. insiders filed 2 open-market purchases and 1 sale; 337 institutions reported holding it in 13F filings for Q2 2026, worth $5.04B in total; Oaktree Capital is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Indivior Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
2 filings
1 insider, $108.0K in total
Open-market sells
1 filing
1 insider, $764.6K in total
Insiders trading
2
Net value
−$656.7K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Indivior Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Indivior Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Anderson Woodrow DChief Accounting Officer27,638Aug 27, 20264
Heidbreder ChristianChief Scientific Officer209,337Jul 13, 20264
Ciaffoni JosephChief Executive Officer790,330Jun 23, 20262
Preblick RyanChief Financial Officer284,751Jun 10, 20264
Ninivaggi Daniel ADirector27,163May 14, 20263
Kingsley Stuart ADirector12,100May 14, 20263
Stejbach MarkDirector27,087May 14, 20263
Thompson JulietDirector12,973May 14, 20262
Wheadon David E.Director30,780May 14, 20263
Ryan BarbaraDirector12,242May 14, 20265
Humphreys KeithDirector16,042May 14, 20263
Burris Jeffrey WChief Legal Officer71,518Mar 5, 20262
Barry Patrick AChief Commercial Officer31,380Feb 12, 20261

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 27, 2026 (view filing)4:00 PM ETAug 27Same dayAnderson Woodrow DChief Accounting OfficerPPurchase+1.50K$35.69+$53.5K+5.7%27.6K after
Aug 5, 2026 (view filing)4:52 PM ETAug 5Same dayAnderson Woodrow DChief Accounting OfficerPPurchase+1.50K$36.28+$54.4K+6.1%26.1K after
Jul 13, 2026 (view filing)4:31 PM ETJul 103 daysHeidbreder ChristianChief Scientific OfficerSSale−18.6K$41.14−$764.6K−8.2%209.3K after10b5-1
Jun 12, 2026 (view filing)Jun 111 dayHeidbreder ChristianChief Scientific OfficerSSale−18.6K$38.06−$707.4K−7.5%227.9K after10b5-1
Jun 10, 2026 (view filing)Jun 82 daysPreblick RyanChief Financial OfficerSSale−36.0K$37.70−$1.36M−11.2%284.8K after10b5-1
Mar 13, 2026 (view filing)Mar 13Same dayRyan BarbaraDirectorPPurchase+8$31.09+$248.72+0.1%5.72K after
Mar 11, 2026 (view filing)Mar 92 daysRyan BarbaraDirectorPPurchase+31$32.56+$1.01K+0.5%5.72K after
Mar 11, 2026 (view filing)Mar 65 daysLateKingsley Stuart ADirectorPPurchase+940$31.87+$30.0K+20.2%5.58K after
Jan 7, 2026 (view filing)Jan 52 daysHumphreys KeithDirectorPPurchase+775$35.39+$27.4K+15.4%5.80K after10b5-1
Jan 7, 2026 (view filing)Jan 52 daysRyan BarbaraDirectorPPurchase+775$35.39+$27.4K+65.2%1.96K after10b5-1
Jan 7, 2026 (view filing)Jan 52 daysWheadon David E.DirectorPPurchase+1.77K$35.39+$62.7K+14.0%14.4K after10b5-1
Jan 7, 2026 (view filing)Jan 52 daysStejbach MarkDirectorPPurchase+775$35.39+$27.4K+4.8%16.8K after10b5-1
Jan 7, 2026 (view filing)Jan 52 daysNinivaggi Daniel ADirectorPPurchase+775$35.39+$27.4K+4.8%16.9K after10b5-1